Co-administration of ASDs and SNEDDS for improving bioavailability of nilotinib compared to ASD alone

Anette Müllertz – Professor, University of Copenhagen; Thomas Rades – Professor, University of Copenhagen

Introduction:

NTB is a ‘brick dust’ molecule (logP 4.5, Tm 236 °C). Its oral bioavailability rises with a high-fat meal ( > 80%), yet low drug solubility in lipids limits its dissolvable dose in lipid-based formulations (LBFs). Addition of NTB by ASD form to SNEDDS can raise its apparent solubility in SNEDDS and delay drug precipitation after dispersion. However, direct ASD-in-SNEDDS may cause phase instability or agglomeration. We therefore adopted a capsule-in-capsule (CiC) approach that combining ASD and a blank SNEDDS, hypothesizing that upon administration, the formed nanoemulsion can solubilize the NTB and the ASD polymer can inhibit NTB precipitation during intestinal digestion.